INSIGHTS ON CLINICAL TRIAL PARTNERING

• Targeted Modalities: Trends, Challenges, CDMO Considerations

  Targeted modalities are designed to bind specifically to receptors or biological targets, ensuring a more directed and effective treatment while reducing systemic exposure and unintended side-effects.

• Navigating Biases In Clinical Trial Vendor Selection

  Biases, often hidden, can distort vendor selection decisions. Recognizing and addressing them across individuals and teams leads to more objective, aligned, and successful clinical trial outcomes.

• Elevating Patient Centricity In Clinical Trials

  How can the integration of patient perspectives throughout the clinical trial process enhance engagement and outcomes?

• Digital Twins: From Protocol Design to Predictive Study Execution

  A growing generation of AI-enabled digital twin approaches offers a new path. Instead of treating the protocol as a static document, organizations can model it as a dynamic system.

• Designing Technology for Real-World Research

  7/31/2026

  From workflow design to smarter notifications, practical site-focused solutions can reduce complexity, improve efficiency, and better support clinical research teams.

• Policy To Practice: PBM Reform, TrumpRx, And Global Drug Development

  3/4/2026

  Policy shifts are reshaping PBM oversight, driving transparent drug‑pricing tools, and influencing global responses that affect affordability, access, and future pharma development.

• Accelerate Drug Development With Master Protocols

  5/15/2025

  Through careful planning, aligned incentives, and an open, adaptive mindset, master protocols become powerful engines for accelerating therapies to market—particularly in high-need therapeutic areas.

• Ethical & Regulatory Considerations For Pediatric Gene Therapy

  5/28/2026

  Understanding risk thresholds, consent requirements, and IRB expectations early can prevent redesign, reduce delays, and improve trial feasibility for vulnerable patient populations

• A New Chapter for Orexin Therapies: What's Changing in Drug Development

  9/16/2026

  Join Beatrice Setnik, PhD and Denise Milova, PhD, for a conversation on orexin rescheduling and the evolving regulatory landscape.